Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.
Schneider-Hohendorf T, Gerdes LA, Pignolet B, Gittelman R, Ostkamp P, Rubelt F, Raposo C, Tackenberg B, Riepenhausen M, Janoschka C, Wünsch C, Bucciarelli F, Flierl-Hecht A, Beltrán E, Kümpfel T, Anslinger K, Gross CC, Chapman H, Kaplan I, Brassat D, Wekerle H, Kerschensteiner M, Klotz L, Lünemann JD, Hohlfeld R, Liblau R, Wiendl H, Schwab N. Schneider-Hohendorf T, et al. Among authors: lunemann jd. J Exp Med. 2022 Nov 7;219(11):e2022065010252022c. doi: 10.1084/jem.2022065010252022c. Epub 2022 Oct 28. J Exp Med. 2022. PMID: 36305889 Free PMC article. No abstract available.
Humoral signatures of MOG-antibody-associated disease track with age and disease activity.
Spatola M, Chuquisana O, Jung W, Lopez JA, Wendel EM, Ramanathan S, Keller CW, Hahn T, Meinl E, Reindl M, Dale RC, Wiendl H, Lauffenburger DA, Rostásy K, Brilot F, Alter G, Lünemann JD. Spatola M, et al. Among authors: lunemann jd. Cell Rep Med. 2023 Feb 21;4(2):100913. doi: 10.1016/j.xcrm.2022.100913. Epub 2023 Jan 19. Cell Rep Med. 2023. PMID: 36669487 Free PMC article.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
EBV-specific T-cell immunity: relevance for multiple sclerosis.
Behrens M, Comabella M, Lünemann JD. Behrens M, et al. Among authors: lunemann jd. Front Immunol. 2024 Dec 24;15:1509927. doi: 10.3389/fimmu.2024.1509927. eCollection 2024. Front Immunol. 2024. PMID: 39776919 Free PMC article. Review.
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis.
Oechtering J, Schaedelin SA, Stein K, Maleska Maceski A, Melie-Garcia L, Benkert P, Cagol A, Leber S, Galbusera R, Ruberte E, Hu W, Qureshi F, Orleth A, Demuth L, Willemse E, Heijnen I, Regeniter A, Derfuss TJ, Fischer-Barnicol B, Achtnichts L, Mueller S, Hoepner R, Lalive PH, Bridel C, D'Souza M, Pot C, Du Pasquier RA, Gobbi C, Zecca C, Wiendl H, Lieb JM, Lamers C, Kappos L, Trendelenburg M, Leppert D, Granziera C, Kuhle J, Lünemann JD; and the Swiss MS Cohort Study. Oechtering J, et al. Among authors: lunemann jd. Neurol Neuroimmunol Neuroinflamm. 2025 Mar;12(2):e200361. doi: 10.1212/NXI.0000000000200361. Epub 2025 Jan 3. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39752618 Free PMC article.
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. Androdias G, et al. Among authors: lunemann jd. Brain. 2024 Dec 21:awae409. doi: 10.1093/brain/awae409. Online ahead of print. Brain. 2024. PMID: 39707906
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
Comabella M, Hegen H, Villar LM, Rejdak K, Sao-Avilés A, Behrens M, Sastre-Garriga J, Mongay N, Berek K, Martínez-Yelamos S, Pérez-Miralles F, Abdelhak A, Bachhuber F, Tumani H, Lycke J, Carbonell-Mirabent P, Valls-Carbó A, Rosenstein I, Alvarez-Lafuente R, Castillo-Triviño T, Otaegui D, Llufriu S, Blanco Y, Sánchez-López AJ, García-Merino A, Fissolo N, Gutiérrez L, Villacieros-Álvarez J, Monreal E, Wiendl H, Montalban X, Lünemann JD. Comabella M, et al. Among authors: lunemann jd. J Neurol. 2024 Dec 12;272(1):26. doi: 10.1007/s00415-024-12763-w. J Neurol. 2024. PMID: 39666032 Free PMC article.
Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Villacieros-Álvarez J, Lunemann JD, Sepulveda M, Valls-Carbó A, Dinoto A, Fernández V, Vilaseca A, Castillo M, Arrambide G, Bollo L, Espejo C, Llufriu S, Blanco Y, Armangue T, Álvarez Bravo G, Quiroga-Varela A, Ramió Torrentà L, Cobo-Calvo A, Tintore M, Mariotto S, Montalban X, Comabella M. Villacieros-Álvarez J, et al. Among authors: lunemann jd. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200340. doi: 10.1212/NXI.0000000000200340. Epub 2024 Dec 11. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39661937 Free PMC article.
Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.
Stascheit F, Sousa CDF, Aigner A, Behrens M, Keller CW, Klotz L, Lehnerer S, Stein M, Herdick M, Doksani P, Gerischer LM, Hoffmann S, Lazaridis K, Tzartos J, Wiendl H, Meisel A, Lünemann JD. Stascheit F, et al. Among authors: lunemann jd. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200331. doi: 10.1212/NXI.0000000000200331. Epub 2024 Nov 27. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39602677 Free PMC article.
146 results